Other drug treatments: the evidence.
Poulter
N
N
Department of Clinical Pharmacology, Imperial College School of Medicine, London, UK. sandra.johnson@ic.ac.uk
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D001241:Aspirin